Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 2, 2015, Pages 137-141

  Subasi, Cemal F ^a   Aykut, Umut E ^a   Yilmaz, Yusuf ^a,b  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

accuracy; diagnostic scores; fibrometer; fibrosis; nonalcoholic fatty liver disease; noninvasive

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE PLATELET RATIO; ASSESSMENT OF HUMANS; BARD SCORE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FIB 4 SCORE; FIBROMETER; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER FIBROSIS SCORE; OUTCOME ASSESSMENT; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; COMPLICATION; EVALUATION STUDY; LIVER CIRRHOSIS; MIDDLE AGED; REPRODUCIBILITY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; THROMBOCYTE COUNT;

ADULT; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PLATELET COUNT; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84920266530     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000255     Document Type: Article

References (31)

1. Smith BW, Adams LA. Non-Alcoholic fatty liver disease. Crit Rev Clin Lab Sci 2011; 48:97-113
2. Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 2013; 19:5169-5176
3. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-Alcoholic fatty liver disease and non-Alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34:274-285
4. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013; 10:627-636
5. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115:209-218
6. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2014 doi: 10.1002/hep.27368 [Epub ahead of print
7. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99:1160-1174
8. Castera L. Assessing liver fibrosis. Expert Rev Gastroenterol Hepatol 2008; 2:541-552
9. Bedossa P. Liver biopsy. Gastroenterol Clin Biol 2008; 32 (Suppl 1):4-7
10. Emanuele E. Is biopsy always necessary?. Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 2008; 48:2086-2087, author reply 2087
11. Denzer UW, Lüth S. Non-invasive diagnosis and monitoring of liver fibrosis and cirrhosis. Best Pract Res Clin Gastroenterol 2009; 23:453-460
12. Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol 2011; 11:91
13. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526
14. Abd El Rihim AY, Omar RF, Fathalah W, El Attar I, Hafez HA, Ibrahim W. Role of fibroscan and APRI in detection of liver fibrosis: a systematic review and meta-Analysis. Arab J Gastroenterol 2013; 14:44-50
15. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57:1441-1447
16. Lee TH, Han SH, Yang JD, Kim D, Ahmed M. Prediction of advanced fibrosis in nonalcoholic fatty liver disease: an enhanced model of BARD score. Gut Liver 2013; 7:323-328
17. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-1325
18. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7:1104-1112
19. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45:846-854
20. Calès P, Lainé F, Boursier J, Deugnier Y, Moal V, Oberti F, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50:165-173
21. Yilmaz Y, Ayyildiz T, Akin H, Colak Y, Ozturk O, Senates E, et al. Gallstone disease does not predict liver histology in nonalcoholic fatty liver disease. Gut Liver 2014; 8:313-317
22. Yilmaz Y, Senates E, Ayyildiz T, Colak Y, Tuncer I, Ovunc AO, et al. Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. Eur J Clin Invest 2012; 42:411-418
23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321
24. Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol (N Y) 2012; 8:661-668
25. Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42:1373-1381
26. Metz CE, Herman BA, Roe CA. Statistical comparison of two ROC-curve estimates obtained from partially-paired datasets. Med Decis Making 1998; 18:110-121
27. Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive assessment of liver fibrosis. Ann Gastroenterol 2012; 25:218-231
28. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple noninvasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-Alcoholic fatty liver disease. Gut 2010; 59:1265-1269
29. Becker L, Salameh W, Sferruzza A, Zhang K, ng Chen R, Malik R, et al. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol 2009; 7:696-701
30. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008; 32 (Suppl 1):22-39
31. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47:455-460